ArticleFrontiers in microbiology2018
PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin.
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- The composition of lung microbiome in lung cancer: a systematic review and meta-analysis.BMC microbiology · 2021Pooled it
- Intratumoral microbiota in the growth of CRC and lung cancer: Comprehensive insights from etiology to therapy.iScience · 2026Review
- Microbial Influence on Immune Checkpoint Inhibitor Therapy in Non-Small Cell Carcinoma: The Gut-Lung-Immune Axis.Cancers · 2026Review
- Lung microbiota analysis in early-stage lung adenocarcinoma.Microbiology spectrum · 2026Article
- Critical assessment of intratumor and low-biomass microbiome using long-read sequencing.bioRxiv : the preprint server for biology · 2026Article
- Microflora: a promising potential in the diagnosis and treatment of non-small cell lung cancer.International journal of clinical oncology · 2026Review
- Research progress in intratumoral microbiota: unlocking the potential of cancer immunotherapy.Frontiers in immunology · 2026Review
- Microbiota relationship between breast, colorectal, and lung cancer types.Medical oncology (Northwood, London, England) · 2025Article
- Microbiome analysis of 940 lung cancers in never-smokers reveals lack of clinically relevant associations.Nature communications · 2025Article
- Comparative microbiome profiling reveals unique signatures in multiple primary lung cancers.Translational cancer research · 2025Article
- The emerging role of microbiota in lung cancer: a new perspective on lung cancer development and treatment.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Lung microbiome dynamics in health and lung cancer.Microbial genomics · 2025Review
- The microbiome in cancer.iMeta · 2025Review
- Race-related host and microbe transcriptomic signatures in triple-negative breast cancer.NPJ breast cancer · 2025Article
- Exploring the metabolomics and metagenomics of chronic obstructive pulmonary disease (COPD) and lung cancer: unraveling the complex interplay.Journal of thoracic disease · 2025Review
- DC-SIGN (CD209)-mediated interactions between bacteria, lung cancer tissues, and macrophages promote cancer metastasis.Infectious agents and cancer · 2025Article
- The role and significance of the oncobiota in selected cancers: a review.Clinical and experimental medicine · 2025Review
- Respiratory microbiota diversity as a predictive biomarker for the efficacy of PD‑1 blockades in patients with advanced non‑small cell lung cancer: A retrospective exploratory study.Oncology letters · 2025Article
- [Research Progress on the Relationship between Intratumor Microbiota and Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- A Perspective on Lung Cancer and Lung Microbiome: Insight on Immunity.Immunity, inflammation and disease · 2025Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is the major form of lung cancer, with adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) being its major subtypes. Smoking alone cannot completely explain the lung cancer etiology. We hypothesize that altered lung microbiome and chronic inflammatory insults in lung tissues contribute to carcinogenesis. Here we explore the microbiome composition of LUAD samples, compared to LUSC and normal samples. Extraction of microbiome DNA in formalin-fixed, paraffin-embedded (FFPE) lung tumor and normal adjacent tissues was meticulously performed. The 16S rRNA product from extracted microbiota was subjected to microbiome amplicon sequencing. To assess the contribution of the host genome,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.